Serum GDF‐15 Levels Correlate With Motor and Nonmotor Symptom Domains and Overall Disease Severity in Patients With Parkinson’s Disease
Parkinson's Disease · 2026-01 · 2026 (1)
DOI: 10.1155/padi/9949931 ↗Kurz gefasst
Fachartikel in der Zeitschrift Parkinson's Disease, online erschienen am 29.04.2026. Verfasst von Noriyuki Miyaue und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, ehime-u.ac.jp. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Objective
Growth differentiation factor 15 (GDF‐15) has emerged as a potential biomarker for neurodegenerative diseases. Although elevated serum GDF‐15 levels have been reported in Parkinson’s disease (PD), their association with clinical features has not been fully characterized.
Methods
We evaluated serum GDF‐15 concentrations in 40 patients with PD and analyzed their relationships with clinical measures, including motor severity (MDS‐UPDRS), quality of life (PDQ‐39), sleep disturbances (PDSS‐2), autonomic symptoms (SCOPA‐AUT), and cognitive function (MoCA‐J).
Results
Higher serum GDF‐15 levels were associated with older age and greater symptom burden across multiple domains. Significant relationships were observed with MDS‐UPDRS Parts I–III and total scores, PDQ‐39 summary index and bodily discomfort index, two different PDSS‐2 domains (motor symptoms at night and PD symptoms at night), and SCOPA‐AUT total and gastrointestinal dysfunction scores. After adjusting for age, the associations between serum GDF‐15 levels and MDS‐UPDRS Part II, Part III, and total scores remained significant. No sex‐related differences were detected. A trend toward lower MoCA‐J scores with increasing GDF‐15 levels was observed but did not reach statistical significance.
Conclusion
Serum GDF‐15 levels are linked to both motor and nonmotor aspects of PD and may reflect overall disease burden. Further longitudinal studies are needed to determine their value for disease monitoring and prognosis.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Therapeutics, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, ehime-u.ac.jp.
- Department of Neurology, Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan.
- Department of Rehabilitation, Saiseikai Matsuyama Hospital, Matsuyama, Ehime, Japan.
ORCID-Profile: Noriyuki Miyaue
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Miyaue, N., Yabe, H., Yasugi, M., & Nagai, M. (2026). Serum GDF‐15 Levels Correlate With Motor and Nonmotor Symptom Domains and Overall Disease Severity in Patients With Parkinson’s Disease. Parkinson's Disease, 2026(1). https://doi.org/10.1155/padi/9949931
Vancouver
Miyaue N, Yabe H, Yasugi M, Nagai M. Serum GDF‐15 Levels Correlate With Motor and Nonmotor Symptom Domains and Overall Disease Severity in Patients With Parkinson’s Disease. Parkinson's Disease. 2026;2026(1). doi:10.1155/padi/9949931
BibTeX
@article{Miyaue2026,
author = {Miyaue, Noriyuki and Yabe, Hayato and Yasugi, Mina and Nagai, Masahiro},
title = {Serum GDF‐15 Levels Correlate With Motor and Nonmotor Symptom Domains and Overall Disease Severity in Patients With Parkinson’s Disease},
journal = {Parkinson's Disease},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/padi/9949931}
}
EUVIMED